Granules India surges as its arm receives Establishment Inspection Report from USFDA
Granules India is currently trading at Rs. 791.05, up by 14.20 points or 1.83% from its previous closing of Rs. 776.85 on the BSE.
The scrip opened at Rs. 780.70 and has touched a high and low of Rs. 793.45 and Rs. 779.95 respectively. So far 515872 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 804.05 on 29-May-2026 and a 52 week low of Rs. 433.00 on 06-Aug-2025.
Last one week high and low of the scrip stood at Rs. 804.05 and Rs. 691.00 respectively. The current market cap of the company is Rs. 19595.78 crore.
The promoters holding in the company stood at 38.02%, while Institutions and Non-Institutions held 32.32% and 29.67% respectively.
Granules India’s wholly-owned subsidiary -- Granules Pharmaceuticals, Inc. (GPI) located in Chantilly, Virginia, US has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), with a Voluntary Action Indicated (VAI) classification.
The inspection was conducted from March 30 to April 3, 2026, during which four Form 483 observations were issued. This facility plays an important role in the company’s global manufacturing and supply network, with a continued focus on quality systems, regulatory compliance, and patient safety.
